Pre-market hot trades in US stocks: VeriSign pre-market down 7.00%; MP Materials pre-market up 3.26%

Pre-market Hot Trades in US Stocks VeriSign is down 7.00% in pre-market trading. Based on recent key news: On July 29, Berkshire Hathaway announced the sale of one-third of its stake in VeriSign, causing the stock price to drop about 6% in pre-market trading. On July 29, VeriSign announced that some shareholders would sell their common stock, leading to a 6.8% drop in the stock price after hours. On July 29, Berkshire Hathaway planned to sell 4.3 million shares of VeriSign stock at a price of $285 to $290 per share, resulting in a 7.1% decline in the stock price in after-hours trading. MP Materials is up 3.26% in pre-market trading. Based on recent important news: On July 29, MP Materials received investment from the U.S. Department of Defense and reached an agreement with Apple, driving the stock price up 3.26%. On July 27, MP reached an agreement with the Department of Defense to establish a rare earth magnet supply chain, enhancing market confidence. On July 26, MP held a monopoly position in the U.S. rare earth market, attracting investor attention. Top Gainers in Pre-market US Stocks Durect is up 265.48% in pre-market trading. Based on recent important news: On July 29, Durect rose 12.8460% in pre-market trading on Nasdaq after receiving feedback from the FDA's breakthrough therapy meeting regarding the Phase 3 trial design of its new drug RED-C, leading to significant market anticipation for its potential to treat hepatic encephalopathy. On July 28, regulatory bans raised concerns in the banking sector; although not directly related to Durect, the market's sensitivity to changes in the financial environment may indirectly affect investor sentiment. On July 29, REC Silicon ASA adjusted its financial report release date; although not directly related to Durect, it reflects the market's emphasis on corporate governance and financial transparency. Salarius Pharmaceuticals is up 146.93% in pre-market trading. Based on recent important news: On June 18, Salarius Pharmaceuticals received a compliance extension from Nasdaq, causing its stock price to rise over 50% and avoiding delisting risk. On June 11, Salarius Pharmaceuticals signed an amendment to the merger agreement with Decoy, adjusting shareholder ownership ratios and impacting market expectations. On June 11, the company's valuation was adjusted to $2.31 million, affecting investor confidence. Calidi Biotherapeutics is up 66.76% in pre-market trading. Based on recent important news: On July 25, Calidi Biotherapeutics announced a 1:12 reverse stock split, leading to a significant increase in the stock price as market expectations changed On July 24th, the company canceled the positions of President and Medical and Scientific Affairs, which may be seen as an internal adjustment that affects investor confidence. On July 25th, the market increased concerns about Calidi's potential inability to obtain FDA approval. Despite the uncertainty, investors remain optimistic about the company's future